BOSTON, MA, Seaport Therapeutics, a clinical-stage biopharmaceuticcal company, announced the closing of a $100 million oversubscribed Series A financing round.
Seaport Therapeutics, a clinical-stage biopharmaceuticcal company that is charting a proven path in neuropsychiatry, announced the closing of a $100 million oversubscribed Series A financing round. The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
